120638-55-3

基本信息
溴酚酸钠
溴芬那酸钠
溴芬酸钠水合物
溴芬那酸钠水合物
溴芬酸钠120638-55-3
(2-氨基-3-(4-溴苯甲酰)苯基)乙酸钠
(2-氨基-3-(4-溴苯甲酰)苯基)乙酸钠水合物
(2-氨基-3-(4-溴苯甲酰)苯基)乙酸钠倍半水合物
Unii-8ecv571Y37
Bromfenac sodiu
Bromfenac ophthalmic
acetate hydrate(2:2:3)
Bromfenac sodium hydrate
BroMfenac sodiuM 1.5H2O
Sodium bromfenate hydrate
Bromfenac ophthalmic solution
Bromfenac Sodium Sesquihydrate
物理化学性质
熔点 | 268-270°C (dec.) |
储存条件 | Refrigerator |
溶解度 | DMSO: ≥ 100 mg/mL (260.98 mM); Water: ≥ 100 mg/mL (260.98 mM) |
形态 | Solid |
颜色 | Light yellow to yellow |
安全数据
警示词 | 危险 |
危险性描述 | H372-H300 |
防范说明 | P260-P264-P270-P314-P501-P264-P270-P301+P310-P321-P330-P405-P501 |
(2-氨基-3-(4-溴苯甲酰)苯基)乙酸钠价格(试剂级)
报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
2025/02/08 | HY-B1888B | (2-氨基-3-(4-溴苯甲酰)苯基)乙酸钠 Bromfenac sodium hydrate | 120638-55-3 | 5 mg | 225元 |
2025/02/08 | HY-B1888B | (2-氨基-3-(4-溴苯甲酰)苯基)乙酸钠 Bromfenac sodium hydrate | 120638-55-3 | 10mM * 1mLin DMSO | 248元 |
2025/02/08 | HY-B1888B | (2-氨基-3-(4-溴苯甲酰)苯基)乙酸钠 Bromfenac sodium hydrate | 120638-55-3 | 10mg | 360元 |
常见问题列表
COX-1 5.56 nM (IC 50 ) |
COX-2 7.45 nM (IC 50 ) |
Bromfenac (90 μg/mL; 48 h) inhibits TGF-b1-induced extracellular matrix (ECM) synthesis and myofibroblast activation in HConFs and HPFs.
Bromfenac (30-90 μg/mL; 48 h) decreases the protein and mRNA expression levels of FN, COL3, a-SMA, and survivin in a dose-dependent manner in HConFs and HPFs.
Bromfenac (30-90 μg/mL; 48 h) declines the phosphorylated protein levels of AKT, ERK1/2, and GSK-3b-S9 with dosage in HPFs and HConFs.
Bromfenac (0.0032-3.16%; 100 or 200 μL; rubbed onto the backs) produces significant anti-inflammatory activity at concentrations as low as 0.1% (4 h pretreatment time) or 0.32% (18h pretreatment time) in rats.
Bromfenac (0.032-3.16%; 100 μL; rubbed onto the paws) produces dose-related anti-inflammatory activity in rats.
Bromfenac (0.032-1.0%; 50 μL) is 26 times more potent than indomethacin in blocking the erythema when applied directly onto the skin area exposed to UV light in guinea pigs.
Bromfenac (0.0032-0.1%; 50μL; rubbed onto the uninjected paw for 4 h per day and 5 days per week) produces a dose and time dependent reduction in the paw volume of both hind limbs in rats.
Bromfenac (0.32%; 50μL; rubbed onto the abdomen) produces significant blockade of abdominal constriction to ACh challenge in mice.
Animal Model: | Male Sprague-Dawley rats (150-250 g) are injected carrageenan |
Dosage: | 0.0032, 0.01, 0.032, 0.1, 0.32, 1.0, 3.16% (100 or 200 μL) |
Administration: | Rubbed onto the backs before 1-72 h of injected carrageenan |
Result: |
Produced significant anti-inflammatory activity when applied 1, 2, and 4 h prior to carrageenan challenge at 0.32%.
Applied 1 or 4 h prior to carrageenan challenge was active, but not when applied 24 h (or longer) prior to challenge at 0.2%. |